JP2017176174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017176174A5 JP2017176174A5 JP2017057024A JP2017057024A JP2017176174A5 JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5 JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- region
- same amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10320408P | 2008-10-06 | 2008-10-06 | |
| US61/103,204 | 2008-10-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226709A Division JP6230983B2 (ja) | 2008-10-06 | 2014-11-07 | Ｍｕｃ１＊抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017176174A JP2017176174A (ja) | 2017-10-05 |
| JP2017176174A5 true JP2017176174A5 (enExample) | 2017-11-16 |
| JP6392923B2 JP6392923B2 (ja) | 2018-09-19 |
Family
ID=42101177
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531128A Pending JP2012504961A (ja) | 2008-10-06 | 2009-10-06 | Ｍｕｃ１＊抗体 |
| JP2014226709A Active JP6230983B2 (ja) | 2008-10-06 | 2014-11-07 | Ｍｕｃ１＊抗体 |
| JP2017057024A Active JP6392923B2 (ja) | 2008-10-06 | 2017-03-23 | Ｍｕｃ１＊抗体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531128A Pending JP2012504961A (ja) | 2008-10-06 | 2009-10-06 | Ｍｕｃ１＊抗体 |
| JP2014226709A Active JP6230983B2 (ja) | 2008-10-06 | 2014-11-07 | Ｍｕｃ１＊抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20170204191A1 (enExample) |
| EP (3) | EP3130607B1 (enExample) |
| JP (3) | JP2012504961A (enExample) |
| KR (1) | KR101455447B1 (enExample) |
| CN (1) | CN102239182B (enExample) |
| CR (1) | CR20110238A (enExample) |
| IL (1) | IL212175B (enExample) |
| WO (1) | WO2010042562A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012504961A (ja) | 2008-10-06 | 2012-03-01 | ミネルバ バイオテクノロジーズ コーポレーション | Ｍｕｃ１＊抗体 |
| KR20160017117A (ko) * | 2008-10-09 | 2016-02-15 | 미네르바 바이오테크놀로지 코포레이션 | 세포내에서 다능성을 유도하기 위한 방법 |
| US8518405B2 (en) * | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| EP3228629A1 (en) * | 2010-06-16 | 2017-10-11 | Minerva Biotechnologies Corporation | Reprogramming cancer cells |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| EP4086338A1 (en) * | 2011-03-17 | 2022-11-09 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| CN102716472A (zh) * | 2011-03-31 | 2012-10-10 | 李光辉 | 一种肿瘤疫苗及其合成方法 |
| WO2014012115A2 (en) * | 2012-07-13 | 2014-01-16 | Minerva Biotechnologies Corporation | Method for inducing cells to less mature state |
| AU2013302620B2 (en) * | 2012-08-14 | 2018-08-02 | Minerva Biotechnologies Corporation | Stem cell enhancing therapeutics |
| WO2014052693A2 (en) * | 2012-09-29 | 2014-04-03 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
| CN103848890B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Muc1自身抗体识别的抗原多肽 |
| US9988442B2 (en) | 2013-01-23 | 2018-06-05 | Syddansk Universitet | MFAP4 binding antibodies blocking the interaction between MFAP4 and integrin receptors |
| CN106132992B (zh) * | 2014-01-29 | 2020-08-07 | 达娜-法勃肿瘤研究所公司 | 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体 |
| CN103880956B (zh) * | 2014-03-10 | 2015-12-30 | 中国人民解放军第四军医大学 | 抗muc1单克隆抗体及其轻链和重链可变区 |
| EP4050103A1 (en) | 2014-04-07 | 2022-08-31 | Minerva Biotechnologies Corporation | Anti-nme antibody |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| MX378108B (es) * | 2014-09-16 | 2025-03-10 | Servier Lab | Anticuerpos anti-met y composiciones. |
| KR102390359B1 (ko) * | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
| CN106999587B (zh) | 2014-10-02 | 2023-09-29 | 希望之城公司 | 多价中间表位，中间表位结合抗体及其用途 |
| EP3204414B1 (en) | 2014-10-07 | 2024-12-04 | Ann and Robert H. Lurie Children's Hospital of Chicago | Novel anti-nodal antibodies and methods of using same |
| EP3256494A4 (en) | 2015-02-10 | 2018-12-05 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| CA3007646A1 (en) * | 2015-12-09 | 2017-06-15 | Bioatla, Llc | Humanized anti-cd73 antibodies |
| EP3450460B1 (en) * | 2016-04-29 | 2023-07-12 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| US20190343953A1 (en) * | 2017-01-27 | 2019-11-14 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| JP7160833B2 (ja) * | 2017-04-13 | 2022-10-25 | サイロパ ビー．ブイ． | 抗ｓｉｒｐアルファ抗体 |
| US12605469B2 (en) | 2017-10-02 | 2026-04-21 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| CN109971713B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途 |
| CN112040985A (zh) * | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| US20200405832A1 (en) * | 2018-03-09 | 2020-12-31 | Minerva Biotechnologies Corporation | Method for anti-muc1* car t cell stimulation |
| WO2020146902A2 (en) * | 2019-01-11 | 2020-07-16 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
| EP3920693A4 (en) | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| WO2021081232A1 (en) | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | Modified cytotoxic t cells and methods of use thereof |
| JP2023530039A (ja) | 2020-06-08 | 2023-07-12 | ミネルバ バイオテクノロジーズ コーポレーション | 抗ｎｍｅ抗体および癌または癌転移の治療方法 |
| CA3183682A1 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| EP4182354A4 (en) * | 2020-07-16 | 2024-12-25 | Dana-Farber Cancer Institute, Inc. | ANTIBODIES AGAINST EXTRACELLULAR DOMAIN/MUC1-C (MUC1-C/ECD) |
| CN116322770A (zh) * | 2020-07-31 | 2023-06-23 | R·P·舍勒科技有限责任公司 | 对粘蛋白-1特异的抗体及其使用方法 |
| KR102811084B1 (ko) | 2020-12-24 | 2025-05-23 | 주식회사 엘지화학 | 뮤신 1에 특이적인 폴리펩티드 및 이의 이용 |
| WO2022156799A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| CA3248038A1 (en) | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES |
| WO2024146536A1 (en) * | 2023-01-04 | 2024-07-11 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-muc1 antibodies and uses thereof |
| US20240261406A1 (en) | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
| EP4587063A1 (en) | 2023-10-11 | 2025-07-23 | Minerva Biotechnologies Corporation | Anti-muc1* antibody drug complexes and uses thereof |
| WO2026064255A1 (en) * | 2024-09-17 | 2026-03-26 | The Trustees Of Columbia University In The City Of New York | Chimeric antigen receptor (car) tregs against pan class i swine leukocyte antigen and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US20020136725A1 (en) * | 1996-01-17 | 2002-09-26 | Smithkline Beecham Corporation | Antithrombotic agents |
| TWI242563B (en) | 1998-04-30 | 2005-11-01 | Tanox Inc | Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor |
| CA2348781A1 (en) | 1998-11-12 | 2000-05-25 | Novolytics Inc. | Compositions and methods for producing vascular occlusion |
| US20020064528A1 (en) | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| WO2001075110A2 (en) * | 2000-03-30 | 2001-10-11 | Dyax Corp. | Mucin-1 specific binding members and methods of use thereof |
| DE60130891T2 (de) | 2000-06-29 | 2008-07-17 | Anthera Pharmaceuticals Inc., San Mateo | Heilmittel für krebs |
| WO2002022685A2 (en) | 2000-09-11 | 2002-03-21 | Kufe Donald W | Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom |
| US7700715B2 (en) * | 2000-11-27 | 2010-04-20 | Minerva Biotechnologies Corporation | Diagnostic tumor markers, drug screening for tumorigenesis inhibition, and compositions and methods for treatment of cancer |
| WO2002078598A2 (en) | 2001-03-29 | 2002-10-10 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Peptides and antibodies to muc 1 proteins |
| US7630836B2 (en) | 2001-05-30 | 2009-12-08 | The Kitasato Institute | Polynucleotides |
| EP1425016B1 (en) | 2001-09-05 | 2010-06-02 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
| CA2478047C (en) * | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| EP1497649A4 (en) | 2002-04-22 | 2006-03-22 | Dyax Corp | FOR MUCIN POLYPEPTIDE SPECIFIC ANTIBODIES |
| ES2524767T3 (es) * | 2002-06-14 | 2014-12-12 | Immunomedics, Inc. | Anticuerpo monoclonal humanizado HPAM4 |
| JP2007531505A (ja) * | 2002-11-27 | 2007-11-08 | ミネルバ バイオオテクノロジーズ コーポレーション | 癌（ｍｕｃ１）の診断および治療のための技術および組成物 |
| US7101978B2 (en) * | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US20060173171A1 (en) | 2003-08-26 | 2006-08-03 | Bamdad Cynthia C | Techniques and compositions for diagnosis and treatment of cancer (muci) |
| EP2168986A3 (en) * | 2004-02-19 | 2010-07-28 | Genentech, Inc. | CDR-repaired antibodies |
| CN101035810B (zh) | 2004-10-04 | 2011-04-06 | 健泰科生物技术公司 | 肝细胞生长因子激活剂的调控物 |
| US8859495B2 (en) * | 2005-03-30 | 2014-10-14 | Minerva Biotechnologies Corporation | Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors |
| US20090075926A1 (en) | 2006-12-06 | 2009-03-19 | Bamdad Cynthia C | Method for identifying and manipulating cells |
| WO2008073817A2 (en) * | 2006-12-08 | 2008-06-19 | Dana-Farber Cancer Institute, Inc. | Muc1 and galectin-3 |
| JP2012504961A (ja) | 2008-10-06 | 2012-03-01 | ミネルバ バイオテクノロジーズ コーポレーション | Ｍｕｃ１＊抗体 |
| AU2013302620B2 (en) * | 2012-08-14 | 2018-08-02 | Minerva Biotechnologies Corporation | Stem cell enhancing therapeutics |
| EP3256494A4 (en) * | 2015-02-10 | 2018-12-05 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
-
2009
- 2009-10-06 JP JP2011531128A patent/JP2012504961A/ja active Pending
- 2009-10-06 CN CN200980148911.6A patent/CN102239182B/zh not_active Expired - Fee Related
- 2009-10-06 KR KR1020117010349A patent/KR101455447B1/ko active Active
- 2009-10-06 EP EP16190400.8A patent/EP3130607B1/en active Active
- 2009-10-06 EP EP09819788A patent/EP2337801A4/en not_active Withdrawn
- 2009-10-06 WO PCT/US2009/059754 patent/WO2010042562A2/en not_active Ceased
- 2009-10-06 EP EP22161931.5A patent/EP4083072B1/en active Active
- 2009-10-06 US US12/574,693 patent/US20170204191A1/en not_active Abandoned
- 2009-10-06 US US15/501,768 patent/US10421819B2/en active Active
-
2011
- 2011-04-06 IL IL212175A patent/IL212175B/en active IP Right Grant
- 2011-05-06 CR CR20110238A patent/CR20110238A/es unknown
-
2014
- 2014-11-07 JP JP2014226709A patent/JP6230983B2/ja active Active
-
2017
- 2017-03-23 JP JP2017057024A patent/JP6392923B2/ja active Active
-
2019
- 2019-08-13 US US16/539,247 patent/US11560435B2/en active Active
-
2022
- 2022-12-06 US US18/062,377 patent/US20230295340A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504907A5 (enExample) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| JP2019524645A5 (enExample) | ||
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| JP2014205674A5 (enExample) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2016185981A5 (enExample) | ||
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2019528240A5 (enExample) | ||
| CN113316591A (zh) | Cd73抗体及其制备方法和应用 | |
| NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| JP2013539454A5 (enExample) | ||
| CN110291109A (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| JP2018537399A5 (enExample) | ||
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. |